Conclusion of US FDS Inspection at our Visakhapatnam, Andhra Pradesh, Finished Dosage (FDF) Unit

21st August, 2026 Corporate Relationship Department The Manager - Listing M/s. BSE Limited M/s. National Stock Exchange of India Ltd Mumbai 400001 Mumbai 400051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir/Madam, Sub:- Intimation under regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 With reference to above cited subject, we bring to your notice that the Company informs the conclusion of U.S. Food and Drug Administration (FDA) Inspection at our Visakhapatnam, Andhra Pradesh, Finished Dosage Formulations (FDF) Unit. This is for your information and records. Thanking you, Yours faithfully, For NATCO Pharma Limited Ch. Venkat Ramesh Company Secretary & Compliance Officer Natco Pharma Limited Regd. Off. Press Release NATCO Pharma Ltd Natco House Road No.2, Banjara Hills Hyderabad-500 034, India Hyderabad, India, August 21st, 2026: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today announced conclusion of US FDA Inspection at our Visakhapatnam, Andhra Pradesh, Finished Dosage Formulations (FDF) Unit Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that: The U.S. Food and Drug Administration (FDA) had conducted an inspection at the Company’s FDF manufacturing plant located in Parawada, Visakhapatnam, Andhra Pradesh, India, which was conducted from August 17th – August 21st, 2026. Upon conclusion of the inspection, the Company has been issued a Form 483 with 4 (Four) observations. The Company believes that the observations are procedural in nature and is confident of addressing these observations comprehensively within stipulated timelines. This is for your information and records. About NATCO Pharma Limited NATCO Pharma Limited (www.natcopharma.com), (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company’s manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at www.natcopharma.com or click on LinkedIn or X (formerly Twitter) For further information please contact: Rajeev Menon, Investor Relations r.menon@natcopharma.co.in/investors@natcopharma.co.in